CMS Launches First Wave HealthTech Ecosystem Tools, 700+ Orgs Pledged
CMS announced the First Wave Launch of its HealthTech Ecosystem, featuring interoperable digital tools for patient data access and streamlined care. Over 700 organizations have pledged support for the initiative, which aims to modernize healthcare delivery by replacing traditional paperwork with digital-first solutions.
Wisconsin DHS Announces $31M Opioid Settlement Fund Allocation Plan
Wisconsin DHS announced its plan to allocate approximately $31 million in opioid settlement funds received in 2025-2026 from settlements with pharmaceutical distributors, manufacturers, and pharmacies. The funds will support prevention programming, substance use disorder treatment, overdose prevention including naloxone distribution, and recovery services across the state including Tribal nations.
Health Canada Consults on Antimicrobial Drug CAN-AWaRe Classification
Health Canada has opened a 60-day public consultation on the proposed Canadian Access, Watch, Reserve (CAN-AWaRe) classification framework for antimicrobial drugs for human use. The consultation runs until June 8, 2026, and seeks feedback from healthcare professionals, industry, academia, and public health agencies on the proposed classification of antibacterial drugs. Comments will inform the finalization of the CAN-AWaRe framework.
Gateway to Health Community Event, April 18, Bismarck
North Dakota HHS announced the fourth annual Gateway to Health community event on April 18, 2026, at Gateway to Science in Bismarck. The free event features over 20 exhibitors offering health resources, interactive activities, and hands-on exhibits for individuals and families.
Recall Mycology Yeastone Broth 11ML Remel - R2609813
ANSM registered safety action R2609813 for Mycology Yeastone Broth 11ML Remel following a lot withdrawal initiated by Thermo Fisher. Medical biology laboratories that received the affected product have been notified directly by Thermo Fisher. This recall addresses a safety concern with specific lots of the reagent used in mycological testing.
Advanced Bionics Cochlear Implant Battery Compartment Recall, 847 Units
ANSM recorded a lot withdrawal by Advanced Bionics LLC for cochlear implant battery compartments (model ZN Air M CI-5501). The action, registered as R2609192, affects 847 units. Health establishments received direct notification from the company with instructions for identifying and returning affected devices.
Elekta Cervical/Intrauterine Brachytherapy System Safety Recall
ANSM published safety alert R2610148 informing healthcare facilities of a medical device safety action by Elekta regarding its cervical/intrauterine brachytherapy system. Users of affected devices have received direct notification from Elekta. The recall is effective April 9, 2026, and healthcare providers using this radiation therapy equipment must take immediate action.
DEX Ophthalmic Forceps Recall Katalyst Surgical Carl Zeiss Meditec
ANSM issued safety alert R2609552 informing French health establishments of a recall by Carl Zeiss Meditec for DEX ophthalmic forceps and scissors manufactured by Katalyst Surgical LLC. Affected health facilities must remove the devices from use and contact the manufacturer directly. The safety action letter was published April 9, 2026.
SFDA and Mawani Convene 220+ Industry Representatives on Supply Chain Resilience
The SFDA CEO hosted a virtual meeting with over 220 representatives from food, pharmaceutical, and medical device companies to discuss supply chain resilience. Key initiatives highlighted include the 'Fast Track' partnership with Mawani for expedited port clearance and the SFDA-Saudia Cargo collaboration for pharmaceutical logistics. The SFDA also detailed its 24/7 Response Center and expanded inspection capacity at ports of entry.
DNV Healthcare Seeks Continued CMS Hospital Accreditation Recognition
CMS published a notice acknowledging receipt of DNV Healthcare USA Inc.'s application for continued recognition as a national accrediting organization for hospital accreditation. The application would allow DNV to continue certifying hospitals for participation in Medicare and Medicaid programs under Section 1865(a)(1)(A) of the Social Security Act. Public comments are being accepted until May 11, 2026.
DNV Healthcare Hospital Accreditation Comment
DNV Healthcare submitted a public comment to CMS on proposed hospital accreditation standards (CMS-2026-1288). The comment was filed through Regulations.gov as part of the federal rulemaking consultation process. The specific content of the comment is not visible in this form submission record.
ML Language Processing Model for Radiotherapy Treatment Planning
USPTO published patent application US20260100265A1 for machine-learning language processing methods used in radiotherapy treatment planning. The system monitors a radiotherapy planning user interface to identify treatment attributes and executes ML models to generate contextual data when thresholds are met. Inventors include Jarkko Peltola, Martin Sabel, Esa Kuusela, Elena Czeizler, Ismo Hautala, and Kellee Donnelly.
Deep Learning Diagnosis of Disease Risk Factors in 3D Biomedical Imaging
The USPTO published patent application US20260100267A1 for deep learning methods and systems that detect biomarkers in volumetric biomedical imaging across optical coherence tomography, ultrasound, magnetic resonance imaging, and computed tomography modalities. The application covers deep neural networks trained to identify clinically useful biomarkers for disease risk factors, filed by Regents of the University of California.
Cloud-Based Interactive Digital Medical Imaging and Patient Health Information Exchange Platform
USPTO published patent application US20260100266A1 by Actual HealthCare Solutions describing a cloud-based platform for integrating clinical records and medical imaging studies using HL7, FHIR, and DICOM standards. The system enables real-time retrieval of patient data from disparate healthcare sources to workstations and mobile devices.
Health Adherence System Patent Published 9th Apr
Health Adherence System Patent Published 9th Apr
Patient-Centered MSK Care System and Associated Therapy Programs
The USPTO published patent application US20260100263A1 for Hinge Health's computer-implemented musculoskeletal (MSK) therapy platform. The platform is designed to improve patient adherence to exercise therapy programs by actively guiding patients through therapy sessions using wearable sensors and coaching. The application was filed December 2, 2025 and published April 9, 2026.
Health Adherence System with Labeling
USPTO published patent application US20260100264A1 for a health adherence system with labeling on April 9, 2026, filed December 12, 2025. The system receives compliance signals from trainees indicating participation in scheduled health events including activity and mental health events. Inventors: Peter Rawlek, Kerri de Zutter, Bryan Poetz.
DEA Baltimore Seizes Over 10,000 Fentanyl-Laced Gel Capsules
DEA Baltimore division and law enforcement partners seized over 10,000 gel capsules containing fentanyl in Baltimore. The counterfeit capsules were packaged to resemble candy or vitamins and were prepared for immediate street distribution. DEA issued a public safety alert warning the public not to be deceived by the deceptive packaging.
Modified LGICs with Altered Ligand Binding, Ion Pore Domains
USPTO published patent application US20260098076A1 for modified ligand-gated ion channels (LGICs) with altered ligand binding domains and ion pore domains. The invention covers exogenous LGIC ligands, methods for modulating ion transport and cell excitability in mammals, and methods for treating channelopathies. The application was filed on February 24, 2025.
Washington University Patents UTI Treatment Using Hemolysin Inhibitor
The USPTO published Washington University's patent application (US20260098073A1) for compositions and methods treating urinary tract infection and sepsis using alpha-hemolysin (HlyA) inhibiting agents. The technology includes soluble LDLR-Fc fusion proteins, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies targeting E. coli hemolysin. This grants Washington University exclusive IP rights over these therapeutic compositions.
Macrocycle and Hydrophobic Particle Method for Removing Polymers from Protein Solutions
USPTO published patent application US20260098055A1 for a method of removing free polymers from solutions containing hydrophobic proteins using macrocycles and/or hydrophobic particles. The application (CPC C07K 1/145) was filed September 7, 2023, with inventors including Barbara Maertens and colleagues. This pre-grant publication does not confer any enforceable rights.
Methods for Constructing Conjugates Using Ortho-Phthalaldehyde
USPTO published Patent Application US20260098054A1 disclosing methods for constructing conjugates using ortho-phthalaldehyde. The method involves reacting an amine-containing component with a thiol-containing component in comparable mole ratios to generate a conjugate bearing a substituted or unsubstituted 1-thio-isoindole structure. Inventors are Xuechen LI and Hey Pui CHEUNG. The application was filed on August 22, 2023.
METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN
USPTO published patent application US20260098077A1 for a method of treating membranous nephropathy using TACI-Fc fusion protein. The application, filed September 28, 2023, discloses dosage schemes, administration intervals, and clinical efficacy data showing good safety profiles in patients.
CAR TCR Cell Therapy Patent Improves Cytokine Signaling
USPTO published patent application US20260098074A1 by inventors Ruth E. Winter and Saikat Banerjee for CAR and/or TCR cell therapy improving cytokine signaling. The patent covers methods for enhancing immune cell function through improved cytokine signaling pathways in cell therapy applications. The application was filed on 2025-07-15.
Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders
USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application
Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.
Methods and Compounds for Restoring Mutant p53 Function
USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.
Novel Crystalline Form of Enavogliflozin and Preparation Method
The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.
2H-Benzotriazole Derivative for Treating Premature Ejaculation
USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.
Heteroaryl Pyridazine Carboxamides For Cancer Treatment
The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.
Multi-Fused Ring Compound for Diabetes, Obesity
USPTO published patent application US20260098037A1 for a multi-fused ring compound targeting diabetes and obesity. The application (filed September 22, 2025 by inventors Baomin Liu, Yan Zhu, Jinfa Hu, and Yu Huang) claims a compound of formula (I), its stereoisomers, and pharmaceutical compositions containing the compound for treating metabolic diseases. This is a routine patent publication providing public notice of the pending application and its claimed scope.
Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors
USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.
Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof
USPTO published Jacobio Pharmaceuticals' patent application (US20260098039A1) for solid forms of Compound I, a potential cancer therapeutic compound, and its salts. The patent covers novel solid forms, preparation methods, pharmaceutical compositions, and therapeutic uses. The application was filed August 16, 2023, and published April 9, 2026.
Digital Stethoscope Dual-Mic Dictation System Captures Physiological Sounds
USPTO published patent application US20260100256A1 for a digital stethoscope system with dual microphones — one capturing physiological sounds and another capturing voice dictation. The system uses noise cancellation to isolate heart and lung sounds from ambient noise. Inventors include Subramaniam Venkatraman, Michael Childs, and others. Medical device manufacturers and healthcare technology developers should review for potential licensing implications.
Oracle EHR Patent Uses LLM Clinical Guidance
Oracle International Corporation filed USPTO patent application US20260100257A1 for a system that uses large language models to analyze clinical guidance from medical sources, generate structured treatment pathways organized by disease state, and integrate them into electronic health record (EHR) patient charts for enhanced clinical decision support.
Vascular Repair Device with Hydrogel and Biodegradable Adhesive
The Nemours Foundation filed US Patent Application US20260097155A1 for a vascular repair device comprising a hydrogel substrate, biodegradable adhesive, and biodegradable mold. The device is designed to surround a target vessel with a trough-shaped containment structure. The application covers medical device innovations in vascular repair technology.
US20260097156A1 - Breast Pump Systems and Methods
The USPTO published patent application US20260097156A1 for breast milk expression systems and methods. The invention covers a breast pump with a flange, milk container, tube, and vacuum pump mechanism configured to express milk from the breast and expel it to a collection container. The application (No. 19350424) was filed on 2025-10-06 by inventors including Jenny Teng, Jason Chamberlain, and Becky Scanlon.
Infusion Pump System with Inductive Sensor Feedback
USPTO published patent application US20260097157A1 for a medical infusion pump system featuring inductive sensor feedback. The system comprises a pump head with a metallic element that cooperates with an inductive sensor on a drive machine, enabling fluid movement through tubing. The application was filed on September 28, 2023.
US Patent for Antimicrobial Coatings, Apr 9
US Patent for Antimicrobial Coatings, Apr 9
Boston Scientific Thrombectomy Devices
USPTO published patent application US20260096828A1 by Boston Scientific Scimed, Inc. covering thrombectomy apparatuses and methods for removing clot material from within a body, including expandable scraper devices and inverting thrombectomy systems with reload capabilities. The application names seven inventors including David Deaton, Christopher K. Huynh, and Michael P. Wallace.
Peritoneal Perfusion Control System With Automated Pumps, Sensors
Peritoneal Perfusion Control System With Automated Pumps, Sensors
Hemodialysis Device With Blood Filtration Pressure Control
The USPTO published patent application US20260097158A1 for a hemodialysis device featuring blood filtration pressure control, filed October 24, 2022, Application No. 18996043, invented by Kosho Matsuzaki and Masayuki Fujii. The device includes a replacement fluid passage between dialysate and blood circuits with first and second flow rate restriction devices, along with connection portion and vein-side pressure sensors. A control device adjusts the second flow rate restriction device opening degree multiple times per cycle based on measured pressures.
Combined Blood Pump and Oxygenator System for Cardiopulmonary Bypass
USPTO published patent application US20260097160A1 for a combined blood pump-oxygenator system designed for cardiopulmonary bypass procedures. The system includes a recirculation loop allowing blood to pass through the oxygenator multiple times for enhanced gas exchange. The application was filed December 10, 2025, by ten listed inventors.
Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.
Recombinant Lubricin Patent - Schmidt and Jay Inventors
USPTO published patent application US20260098069A1 for recombinant isoforms of human-like lubricin (PRG4 glycoprotein) invented by Tannin A. Schmidt and Gregory D. Jay. The patent covers new lubricin isoforms with novel glycosylation patterns and methods for commercial-scale manufacturing using recombinant production methods.
GLP-1 Analog for Treatment of GLP-1 Related Diseases
USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.
SMAGP Fusion Molecules Modulate Leukocyte Activity
USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.
DWORF Peptide SERCA Pump Activator Heart Failure Treatment
The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.
P80 Protein Treatment Method Using Pharmaceutical Composition Comprising Neurotoxin Associated Polypeptide
The USPTO published patent application US20260098066A1 assigned to Prime Bio, Inc., covering a method of treating disorders using a pharmaceutical composition comprising a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 acts as a tight junction modulator to enhance intestinal epithelium permeability, facilitating drug delivery and increasing bioavailability of therapeutic agents including drugs, small molecules, proteins, and biomolecules.
GC-Globulin Patent Claims Diabetes Treatment
USPTO published patent application US20260098068A1 for GC-globulin or variants for treating diabetes, filed September 22, 2023. The application names David Hodson, Katrina Viloria, and Martin Hewison as inventors and covers compositions and methods for diabetes treatment using the vitamin D-binding protein.
MITSUI CHEMICALS Carbamate Compound Patent Application
MITSUI CHEMICALS, INC. published a patent application (US20260098022A1) for a carbamate compound with specific molecular structure parameters. The application describes compounds where R1-R4 form monocyclic or polycyclic rings through various substituent linkages. CPC classifications include C07D 295/205, C07C 271/44, and C07C 275/32. Competitors developing similar chemical structures should review claims upon grant.
Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment
USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.
Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds
USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.
Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative
USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.
M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia
The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.
Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment
USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.
PARP1 Inhibitors and Uses Thereof
USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.
Rhodium Catalyst Method for Hydrogenation of Furfural to Bio-Fuel
The USPTO published patent application US20260098023A1 by King Fahd University of Petroleum and Minerals, covering a method for hydrogenating furfural to furfuryl ethyl ether bio-fuel using a rhodium nanoparticle catalyst (0.9-1.1 wt.% on alumina). The reaction achieves at least 99% conversion and 99% selectivity under ethanol and hydrogen atmosphere.
Oracle Semantic EHR Knowledge Relationships System
Oracle International Corporation has filed patent application US20260099732A1 for a system that integrates proprietary and standardized medical terminologies into electronic health record systems. The system creates a knowledge graph incorporating both terminology types and analyzes patient data against this graph to generate clinical decision support suggestions for the EHR system. Healthcare software developers and EHR vendors should monitor this application for potential implications on semantic interoperability in clinical systems.
Automatic Analyzer Calculating Sample and Consumable Replacement Wait Times
USPTO published patent application US20260098871A1 by Hitachi High-Tech Corporation for an automatic analyzer that calculates waiting times for sample and consumable replacement based on analysis schedules. The invention aims to improve laboratory workflow efficiency by determining optimal timing for replacing samples or consumables. The application was originally filed on August 23, 2023.
Active Premix for Antiperspirant Products Patent Application
The USPTO published patent application US20260096962A1 covering a particulate active premix composition for antiperspirant products. The composition combines basic aluminum chloride of formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952, an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. Inventors: Wade Charles Henke, Shawn David McConaughy, and David Frederick Swain.
L'OREAL UV Absorbing System with Oil for Preventing Material Aggregation
The USPTO published L'OREAL's patent application (US20260096963A1) for a UV absorbing composition combining physical UV-attenuating materials with oils to inhibit particle aggregation. The invention targets improved stability in sunscreen and cosmetic formulations. The application was filed on October 4, 2024, under application number 18906290.
UV-Absorbing Emulsion with Physical UV-Attenuating Material, Surfactant, and Thickener
USPTO published L'OREAL's patent application (US20260096964A1) for UV-absorbing emulsion compositions containing physical UV-attenuating material, surfactant, and thickening agents. The application was filed on October 4, 2024, under Application No. 18906424. Inventors include Anil Shah, David Enoch Gee II, Brian Bodnar, and Margaret Kindschuh. This patent publication affects cosmetics and personal care product manufacturers developing UV-protective formulations. Companies should review the claims to assess potential overlap with their own product development pipelines and IP strategies.
L'OREAL UV Emulsion Patent with Physical UV-Absorbing System
USPTO published L'OREAL's patent application US20260096965A1 for emulsion compositions containing a UV-absorbing system with physical UV-attenuating material and spherical plus amorphous particulate materials. The patent covers methods of making and using such compositions for UV protection. The application was filed October 4, 2024.
Active Premix Aluminum Zirconium Salts Antiperspirant
USPTO published patent application US20260096968A1 by Wade Charles Henke, Shawn David McConaughy, and David Frederick Swaile covering a particulate active premix composition containing an aluminum zirconium salt, an amino acid, and greater than 1% of an alkali metal salt for use in antiperspirant products.
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
L'OREAL UV Absorbing Composition with Physical Filters and Three Emollients
USPTO published L'OREAL's patent application (US20260096966A1) for a UV-absorbing composition combining at least one physical UV-attenuating material with an emollient system containing at least three emollients. The invention includes methods of making and using such compositions for topical applications. The application was filed on October 3, 2025, under Application No. 19349244.
UV Absorbing System With Physical Material Coloring Agent
USPTO published L'OREAL's patent application (US20260096967A1) for UV-absorbing compositions containing physical UV-attenuating materials and coloring agents. The application covers methods of making and using such cosmetic compositions for sun protection. The application was filed October 3, 2025.
Metal Guide Tube, Deformable Shape-Retention, Medical Device
USPTO published patent application US20260097229A1 for a deformable metal guide tube with shape-retention function designed for medical instrument guidance and insertion into treatment target sites, filed by inventor Hideki KANEBAKO on December 12, 2025.
Devices for Treating Postpartum Hemorrhaging
USPTO published patent application US20260097205A1 by Meditrina, Inc. for devices treating postpartum hemorrhaging. The application covers electronic stimulation devices (CPC: A61N 1/36007, A61M 1/77) intended for treatment of this critical maternal health condition. Inventors include Csaba Truckai, Akos Toth, and John H. Shaddduck. Filing date was October 8, 2025.
Motor Drive Circuit for Mechanical Circulatory Support Device Patent Application
USPTO published patent application US20260097195A1 for a motor drive circuit designed for mechanical circulatory support devices such as ventricular assist devices. The invention discloses methods for generating PWM drive signals, selectively filtering the signals, sensing back EMF to determine rotor position, and modifying drive signals accordingly. Inventors include Hisham Hafez, Johannes Visser, and Verena Zscherlich.
Heart Assistance Device, BYPA Medical Solutions, Apr 9
USPTO published patent application US20260097196A1 for a heart assistance device developed by BYPA Medical Solutions. The device uses a linear actuator to move a membrane in a chamber, creating pulsating fluid flow synchronized with patient ECG signals. The control unit calculates timing offsets between QRS complex detection and ejection phase initiation.
Intravascular Blood Pump With Expandable Impeller
USPTO published patent application US20260097197A1 for an intravascular blood pump featuring an expandable impeller housed within a blood conduit. The application, filed September 26, 2025 (No. 19342411), covers catheter-based pump technology with expandable pump portions and impellers designed to operate within blood lumens between inflow and outflow regions. Inventors include Michael Calomeni, Brian D. Brandt, Daniel Hildebrand, and Tom Saul.
4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA
The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration
The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.
Targeted Amatoxin Conjugate for Treatment of Solid Tumors
Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.
DBI Protein Modulation Methods for Autophagy and Metabolic Regulation
The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.
Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases
The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.
Painless NGF Compositions for Fracture Repair
The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.
Dextrorphan Amino Acid Ester Stereoisomer Conjugates with Improved Bioavailability
The USPTO published patent application US20260098013A1 disclosing amino acid ester conjugates of dextrorphan using diastereomerically pure amino acids to improve bioavailability. Inventors include Sven Guenther, Travis Mickle, Sanjib Bera, and Amarraj Chakraborty. The application covers pharmaceutical compositions and methods of treating diseases using these conjugates.
Crystalline Imidazole Polymorphs for Mitochondria and Cardiovascular Treatment
USPTO published patent application US20260098015A1 for crystalline polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. The compound is directed to treating mitochondria-related disorders and cardiovascular disorders or conditions. The application was filed May 19, 2025 and names Muralikrishna DUVVURI, Donald Herbert LAMUNYON, and Micah Jeffrey BODNER as inventors.
Method and System for Fully Continuous-Flow Preparation of Nitroimidazole Antimicrobial Agent
USPTO published patent application US20260098016A1 for a fully continuous-flow method of synthesizing nitroimidazole antimicrobial agents. The method uses glyoxal aqueous solution, acetaldehyde aqueous solution, and ammonium hydroxide as raw materials through multi-step chemical reactions. Inventors include Fener Chen, Minjie Liu, Li Wan, Yajiao Zhang, Xingpeng Cai, and Zhisheng Yang. The system includes micromixers, microreactors, back pressure valves, gas-liquid separators, and online solvent switching units.
Novel Aromatic Ring Derivative Containing Amide Substitution as TYK2 Inhibitor
The USPTO has published patent application US20260098017A1 for a novel aromatic ring derivative containing amide substitution as a TYK2 inhibitor for treating inflammatory and autoimmune diseases including psoriasis, psoriatic arthritis, dermatitis, lupus, inflammatory bowel disease, and rheumatoid arthritis. The application was filed December 22, 2023, with inventors including Wenzhi Wang, Shuangyong Sun, and colleagues. The invention demonstrates therapeutic efficacy in psoriasis and asthma animal models with good druggability, stability, and safety profiles.
Bicyclic 1,4-Diazepanones and Therapeutic Uses
The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.
NSAID Conjugate Anti-Inflammatory Compounds Via Microwave Synthesis
The USPTO published patent application US20260098019A1 for microwave-synthesized NSAID conjugate compounds containing triazolyl heterocycles. The compounds are derivatives of FDA-approved anti-inflammatory drugs such as ibuprofen and indomethacin. The application claims improved anti-inflammatory efficacy with reduced ulcerogenic effects and selective COX-2 inhibition over COX-1.
Tetrahydroacridinone Analogues for Malaria Treatment and Prevention
The USPTO published patent application US20260098012A1 for tetrahydroacridinone scaffold molecules exhibiting antimalarial activity against multiple Plasmodium spp. strains in erythrocytic and exoerythrocytic stages. The application, filed December 11, 2025, names 11 inventors including Dennis E. Kyle and Steven Maher and covers pharmaceutical compositions for malaria treatment and prevention.
Ionizable Lipidoid Compositions and Therapeutic Uses Thereof
Ionizable Lipidoid Compounds for Therapeutic Agent Delivery
Deuterated Organic Compounds for Schizophrenia and Depression Treatment
The USPTO published patent application US20260098011A1 covering deuterated organic compounds of Formula I and II for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating disorders including schizophrenia and depression. The application was filed on June 11, 2025, under application number 19235237.
Ultra-Long-Acting Platform Comprising Fc-Advanced Fatty Acid Chain Extending Drug Half-Life
The USPTO published patent application US20260097125A1 for an ultra-long-acting drug delivery platform combining immunoglobulin Fc with a modified C14-24 fatty acid chain. The conjugated molecule structure 'active molecule-Fc-Cn' is designed to extend the half-life of therapeutic active molecules. The application was filed on September 22, 2023, with eight inventors including Faming Zhang, Yimin Hu, and colleagues.
Blaine Labs Recalls Revitaderm and Tridergel Wound Care Gel Due to Microbial Contamination
Blaine Labs, Inc. has voluntarily recalled three lot numbers of Revitaderm and Tridergel Wound Care Gel products (BL3608, BL3435, BL3525) distributed nationwide to healthcare providers due to contamination with Lysinibacillus fusiformis, an environmental spore-forming bacterium. The contaminated 1 oz. and 3 oz. antiseptic wound gels pose infection risk to patients with open wounds, compromised skin barriers, or weakened immune systems.
Boston Scientific Pleated Outer Skirt Heart Valve
The USPTO published Boston Scientific Scimed, Inc.'s patent application for a replacement heart valve featuring a pleated outer skirt design. The invention comprises an expandable framework with a coupled outer skirt containing multiple pleats, classified under CPC codes A61F 2/2418 and A61F 2/2415. Medical device manufacturers and cardiac implant developers should monitor this application for potential competitive implications in the heart valve market.
Apparatus and Methods for 3D Printing Intraocular Lens Components
USPTO published patent application US20260096877A1 for Alcon Inc., covering apparatus and methods for 3D printing intraocular lens components, including formulations with monomers, crosslinkable polymers, crosslinkers, and photoinitiators. The patent also discloses a 3D printer system with reservoir, build platform, light source, and projection optics for curing lens layers. The application was filed September 11, 2025, with application number 19326387.
Stent-Graft Prosthesis System and Delivery Method
USPTO published Swiss Capital Engineering AG's patent application for a stent-graft prosthesis system with improved delivery mechanism. The invention includes a main body with lateral side branches and a guiding element for navigation to branch vessels. The system features textile threads with radiopaque markers for enhanced procedural visualization.
Low Profile Stent Graft And Delivery System
USPTO published patent application US20260096875A1 for a low profile stent graft and delivery system, filed October 3, 2025 by inventors Vinluan et al. The invention covers a tubular prosthetic device for implantation into body lumens with a first part including a tubular lumen and a second part with an attachment member, designed to achieve a reduced diameter for ease of implantation.
Surgical Planning System for THA Using 3D Imaging
USPTO published patent application US20260096854A1 for a surgical planning system enabling pre-operative planning for total hip arthroplasty (THA) procedures. The system displays patient musculoskeletal structure images, co-registers them with spatial transformations, and renders 3D implants overlaid on images with safe zones indicating clinically accepted positioning ranges. The application enables surgeons to compare available implant options and their respective range-of-motion characteristics during pre-surgical planning.
Valve-In-Valve Risk Assessment Systems and Methods
USPTO published patent application US20260096852A1 by Spencer et al. disclosing systems and methods for evaluating risks of valve-in-valve cardiac procedures where a replacement transcatheter aortic valve is deployed within an existing bioprosthetic valve. The invention involves receiving patient anatomy images, obtaining anatomical measurements, comparing against predetermined benchmarks, and evaluating procedural risks.
Large Bore Sheath Device Including Coupling Device
Large Bore Sheath Device, Silk Road Medical, Apr 9
TEE-Guided Valve Implantation System
USPTO published patent application US20260096880A1 by Anumana, Inc. for a transesophageal echocardiogram-guided system that generates 3D cardiac models from ultrasound images to guide cardiovascular valve device implantation. The system includes TEE ultrasound components, computing devices for image processing and 3D model interpolation, and display capabilities for synchronized valve model visualization.
CroiValve Cardiac Valve Prosthetic with Anti-Migration Features US20260096878A1
CroiValve Patent A1, Apr 9, Cardiac Valve Treatment
Edwards Lifesciences Valve Expansion Monitoring Patent Application
USPTO published patent application US20260096881A1 for Edwards Lifesciences Corporation on April 9, 2026. The application covers a prosthetic valve delivery apparatus with an indicator arm system configured to monitor valve expansion diameter at predetermined sizes. Medical device manufacturers developing cardiac valve delivery systems should monitor this publication for patent landscape implications.
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Universal Peptide/MHC Complexes with Engineered Disulfide
The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.
Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity
USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.
Delivery Device for Positioning an Expander in a Prostatic Urethra
USPTO published patent application US20260096911A1 for a delivery device used to position an implantable expander in a prostatic urethra for treatment of benign prostatic hyperplasia. The application, filed December 11, 2025, covers six inventors and describes a resiliently deformable biocompatible expander configured to exert outward radial force against the urinary duct wall.
Image-Assisted Delivery of an Expander in a Urethra for BPH Treatment
The USPTO published patent application US20260096914A1 for an image-assisted delivery device designed to implant a biocompatible expander in the urethra for treatment of benign prostatic hyperplasia (BPH). The expander is configured for implantation into the prostatic urethra spanning between the bladder neck and external sphincter. The application was filed on December 11, 2025, and published on April 9, 2026.
Catheter Deploys Urethra Expander for BPH Treatment
The USPTO published patent application US20260096913A1 for a catheter system designed to deploy an implantable biocompatible expander within the prostatic urethra for treatment of benign prostatic hyperplasia. The device is resiliently deformable for transluminal delivery and configured to exert outward radial force against the urethral wall once implanted between the bladder neck and external sphincter.
Urethral Expander Catheter for Benign Prostatic Hyperplasia
USPTO published patent application US20260096912A1 for a catheter system to deploy an implantable urethral expander for treating benign prostatic hyperplasia (BPH). The expander is biocompatible, resiliently deformable, and configured to exert outward radial force against the prostatic urethra between the bladder neck and external sphincter. Medical device manufacturers and urological treatment developers should monitor this filing for potential freedom-to-operate implications.
TheraNova Foley Catheter Urinary Sensing Patent Application
USPTO published patent application US20260096760A1 by TheraNova LLC for a Foley-type catheter system with integrated physiologic sensors. The invention includes pressure sensors and transducers for monitoring bladder and peritoneal pressure, respiratory rate, cardiac rate, and other hemodynamic parameters via urinary tract access. The published application covers catheter embodiments, data processing methods, and system configurations for continuous patient health monitoring.
Multi-Channel Automatic Infusion Valve for Surgical Fluid Control
USPTO published patent application US20260096923A1 for a multi-channel automatic infusion valve designed for surgical fluid control. The invention includes a valve body with multiple conduits and ports, a hydrophobic filter extending across a cavity, and an activation member for managing fluid delivery and aspiration during medical procedures.
Multi-Layer Urine Capture Device for Female Users
The USPTO published patent application US20260096936A1 by Samuel Edmund Whittome et al. for a multi-layered urine capture device designed for female users. The device includes fluid permeable layers, absorbent layers, hydrophobic layers, and fluid impermeable layers positioned adjacent to the urethra. Patent applications are published to make inventions publicly available and do not yet confer patent rights.
Cell Behavior Control Methods Without Genetic Modification
USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.
Erythroid Lineages from Pluripotent Cells
USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.
Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation
USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.
Modified Gamma Delta T Cells for Cancer Therapy
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment
USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.
Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment
The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.
Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE
The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).
Human Hair Follicle-Derived Conditioned Media and Method of Making Same
USPTO published patent application US20260097082A1 covering methods for preparing hair follicle-derived conditioned media containing bioactive factors. The hair follicles are retrieved non-invasively and cultured to secrete therapeutic compounds. The application covers compositions for therapeutic and cosmetic treatments including hair restoration and skin repair.
PTGS2 Skin Disorders Carnosine Compound Treatment Method
USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.
Ammonium Chloride Formulations for Viral Defense
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application
USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.
Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
Aerosol Antiperspirant Composition with Basic Aluminum Chloride Salt Formula
USPTO published patent application US20260096955A1 for an aerosol antiperspirant composition containing a basic aluminum chloride salt (formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952), an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. The concentrate includes a particulate active premix, carrier, and fragrance. The application names five inventors and was filed October 3, 2025.
Liposome Composition Comprising Sphingomonas Olei Culture Extract for Skin Delivery
USPTO published patent application US20260096958A1 by six inventors including Won Woo Choi and Byong Jun Choi for a liposome composition encapsulating Sphingomonas olei culture extract for enhanced skin regeneration and transdermal absorption. The application covers cosmetic compositions for topical skin delivery applications, classified under CPC codes A61K 8/14 and A61Q 19/00.
ORR Requests 3-Year Extension for Unaccompanied Refugee Minors Program Forms
The Office of Refugee Resettlement (ORR) within ACF is requesting a 3-year extension with revisions to the Unaccompanied Refugee Minors (URM) Program Application and related withdrawal/declination forms (OMB #0970-0550). The proposed revisions include reducing open-ended text box questions by 67 percent, changing question formats for quicker responses, cutting unnecessary questions, and revising instructions for clarity. Estimated total annual burden hours are reduced by 48 percent.
Pennsylvania Expands On-the-Spot Birth Certificate Initiative for Reentrants
The Pennsylvania Departments of Health, Labor & Industry, and Corrections jointly hosted an on-the-spot birth certificate issuance event at Kintock, a reentry community corrections center, on April 8, 2026. The Division of Vital Records issued over 30 birth certificates to residents, removing a key barrier to employment, housing, and identification that reentrants commonly face.
NC invests $5.7M in substance use services for underserved areas
NCDHHS announced $5.7 million in federal block grant funding to 12 community-based organizations to expand substance use disorder services in underserved North Carolina communities. Awards range from $287,000 to $500,000 per recipient with potential renewal for up to two additional years based on federal fund availability.
Procedures for Requests From Tribal Lead Agencies To Use CCDF Funds for Construction or Major Renovation
The Office of Child Care (OCC) under HHS proposes to extend and modify an existing information collection for Tribal Lead Agencies requesting Child Care and Development Fund (CCDF) funds for child care facility construction or renovation. The updated Program Instruction significantly streamlines requirements, reducing burden by 70% from 20 hours to 6 hours per response, cutting 19 pages and eliminating 5 requirements while maintaining statutory compliance under 42 U.S.C. 9858m(c)(6). Comments are due May 11, 2026.
LIHEAP Household Data Collection Report Reinstatement Request
HHS Administration for Children and Families proposes to reinstate the LIHEAP Household Report (OMB #0970-0060) with proposed changes to reduce reporting burden. States, DC, and Puerto Rico would submit household statistics by assistance type and funding source, while tribal grantees would submit simplified household counts. Comments are due June 8, 2026.
Annual Survey of Refugees Information Collection Extension Request
The Administration for Children and Families (ACF) seeks OMB approval to extend the Annual Survey of Refugees (ASR) through 2027, maintaining the existing survey form for the 2025 and 2026 collection cycles. The ASR collects data from approximately 6,400 refugee households that entered the U.S. within the previous 5 fiscal years, supporting the Office of Refugee Resettlement's congressional reporting requirements under the Refugee Act of 1980.
DNV Healthcare Hospital Accreditation Program Continued Approval Application
CMS published notice of DNV Healthcare USA Inc.'s application for continued recognition as a national accrediting organization for its hospital accreditation program under Medicare and Medicaid. The agency seeks public comment on whether DNV meets CMS standards for continued approval. Comments must be submitted by May 11, 2026.
National Eye Institute Board of Scientific Counselors Closed Meeting Notice
The NIH National Eye Institute published a closed meeting notice for the Board of Scientific Counselors on April 27, 2026. The meeting will review and evaluate personnel qualifications and performance, and the competence of individual investigators. The meeting is closed pursuant to FACA exemptions for personal privacy.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review published a notice announcing five closed meetings scheduled for May 5-6, 2026, to review grant applications across topics including aging/neurological/behavioral health, cardiovascular clinical trials, cancer genetics, gene regulation, and pathogenic eukaryotes. All meetings will be held virtually and closed to the public pursuant to the Federal Advisory Committee Act.
HRSA Extends Small Health Care Provider Quality and Delta States Network Programs
HRSA has issued a notice extending two grant programs for rural healthcare providers. The Small Health Care Provider Quality Improvement Program receives a 1-year extension for 21 award recipients (HRSA-22-093 cohort), while the Delta States Network Development Program extends 12 award recipients (HRSA-23-031 cohort). Total funding amounts to $15,928,583 for the period August 1, 2026, through July 31, 2027.
Block Grants and Community Services Programs Deregulation
The Department of Health and Human Services, Administration for Children and Families proposes to amend three regulatory frameworks—45 CFR Part 96 (Block Grants), 45 CFR Part 1000 (Individual Development Account Reserve Funds), and the Emergency Community Services Homeless Grant Program regulations—to eliminate unnecessary or obsolete provisions. The proposed deregulatory action affects seven major block grant programs including Community Services Block Grant, LIHEAP, and maternal health services, with written comments due by May 8, 2026.
Rescinding Obsolete State Legalization Impact Assistance Grants Regulations
The Department of Health and Human Services, Administration for Children and Families has issued a direct final rule rescinding obsolete provisions of 45 CFR part 402, which governed the State Legalization Impact Assistance Grants (SLIAG) program. The SLIAG program, established by the Immigration Reform and Control Act of 1986 to reimburse states for costs associated with newly legalized aliens seeking public benefits, has long since concluded. The rule removes these outdated regulatory provisions effective May 26, 2026, unless significant adverse comments are received by that date.
HHS Proposes to Rescind Obsolete Repatriation Program Regulations
The Administration for Children and Families (ACF) published a Notice of Proposed Rulemaking to rescind obsolete and duplicative regulations in 45 CFR parts 211 (Care and Treatment of Mentally Ill Nationals Returned from Foreign Countries) and 212 (Assistance for U.S. Citizens Returned from Foreign Countries). The proposal targets regulations that are redundant with existing statutes, overly prescriptive technical requirements better suited for sub-regulatory guidance, and entirely obsolete provisions. Public comments are due April 27, 2026.
Native American Programs Act Regulations - Deregulation
The Department of Health and Human Services, Administration for Children and Families (ACF), proposes to amend 45 CFR part 1336 to eliminate unnecessary or obsolete regulations under the Native American Programs Act. The NPRM targets duplicative regulations, provisions better suited for sub-regulatory guidance, and entirely obsolete requirements. Comments must be received by April 27, 2026.
Boil Water Advisory Rescinded for McCune After Testing
KDHE has rescinded the boil water advisory for the City of McCune in Crawford County, Kansas, after laboratory testing confirmed no evidence of bacteriological contamination. The advisory was originally issued following a waterline break that caused loss of pressure in the distribution system. All conditions that placed the water system at risk of contamination are now deemed resolved by KDHE officials.
NMMB Board Actions Quarter 1 2026 - 15 Practitioner Discipline Orders
The New Mexico Medical Board issued 15 disciplinary orders against medical practitioners in Q1 2026 (January through March). Actions include Notices of Contemplated Action, Stipulations for Withdrawal of Licensure Applications, and Orders of Reprimand. Violations cited include conduct likely to deceive or harm the public, patient abandonment, injudicious prescribing, medical record mismanagement, and failure to cooperate with board investigations.
Trauma Advisory Council Data and PI Subcommittee Meeting - April 10, 2026
Trauma Advisory Council virtual meeting, Apr. 10, 9am
Projected Reality variance application, FDA, California, Apr 8
Projected Reality variance application, FDA, California, Apr 8
DOH Joins Global Outbreak Alert and Response Network
The Hawaii Department of Health announced its membership in the WHO-established Global Outbreak Alert and Response Network (GOARN) on March 19, 2026. Hawaii becomes part of a network of over 300 technical institutions providing coordinated response to disease outbreaks and public health emergencies worldwide. The DOH will contribute expertise in surveillance, laboratory testing, and emergency response for Pacific region health crises.
Nucletron B.V. Intrauterine Tube Recall - Tip Detachment
Health Canada issued a Type II medical device recall for Nucletron B.V. Intrauterine Tubes (catalog numbers 152019-00 through 126015-01) affecting 44 product lots. The recall addresses a safety concern where the tip of the 4mm diameter IU tube detached and remained within a patient during use. Healthcare providers should contact the manufacturer for additional information.
ACE Surgical sutures recall due to unlicensed medical devices
Health Canada issued a Type II recall for ACE Surgical Supply® PGA Absorbable Sutures and Absorbable Gut Sutures distributed in Canada. BioHorizons Canada is conducting the recall because manufacturer ACE Surgical Supply Co. Inc. voluntarily ceased operations and discontinued its medical device licenses in Canada, resulting in unlicensed devices on the market. All lots of 17 affected catalogue numbers are subject to this recall. Healthcare providers who have distributed these sutures must cease use and contact the importer.